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Abstract: The objective was to determine the disposition of polymer nanoparticles and an 
associated, lipophilic, model “active” component on and within the skin following topical 
application. Polystyrene and poly(methyl methacrylate) nanoparticles containing covalently 
bound fluorescein methacrylate and dispersed Nile Red were prepared by emulsion 
polymerization. The two fluorophores differentiate the fate of the polymeric vehicle on and 
within the skin from that of the active. Nanoparticles were characterized by dynamic light 
scattering, transmission electron microscopy and NMR spectroscopy. In-vitro skin 
permeation experiments were performed using dermatomed porcine skin. Post-treatment 
with nanoparticle formulations, the skin surface was either cleaned carefully with buffer, or 
simply dried with tissue, and then immediately visualized by confocal microscopy. Average 
nanoparticle diameters were below 100 nm. Confocal images showed that nanoparticles 
were located in skin “furrows” and around hair follicles. Surface cleaning removed the 
former but not all of the latter. At the skin surface, Nile Red remained partly associated 
with nanoparticles, but was also released to some extent and penetrated into deeper layers 
of the stratum corneum (SC). In summary, polymeric nanoparticles did not penetrate 
beyond the superficial SC, showed some affinity for hair follicles, and released an 
associated “active” into the skin. 
 
Keywords: Nanoparticles; skin; laser scanning confocal microscopy (LSCM); topical drug 
delivery. 
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Introduction 
Recently, polymeric nanoparticles (NP) have been proposed as carriers for drugs and other 
active agents administered by topical administration. Examples include anti-inflammatory drugs,1, 2 
anti-infective drugs, vitamins3 and sunscreens.4-6 It has been claimed that drug-loaded NP achieve 
sustained release and consequently improve the therapeutic effect of dermatological formulations.2, 3 
More importantly, NP can increase the stability of sensitive actives by protecting the molecules in a 
polymeric shell. Based on this, NP have been incorporated into several commercially available 
cosmetic products to encapsulate various actives (e.g., vitamin A, rose extract and wheat germ oil).  
The development of topical formulations containing nano-sized materials has also been 
challenged by mechanistic and toxicity issues. Compared with larger particles, it has been suggested 
that nanostructures are more likely to penetrate the stratum corneum and gain access to the living 
cells within the epidermis and dermis. Should this be possible, then systemic exposure might occur 
(i.e., the nanoparticles being taken up into the blood and distributed to various tissues and organs), 
presenting thereby a potential toxicity risk for human health.7-10 Therefore, understanding the 
topical disposition of both vehicle and active is essential for the use of nano-engineered topical 
formulations. Whether (and when) the active is released from the vehicle, and the fate of the vehicle 
itself, are very important questions concerning the safety of nanotechnology. To address these issues, 
two series of polymeric NP have been prepared in which the polymer was covalently-labelled with 
fluorescein methacrylate (FMA, Chart 1a). A second fluorescent compound, Nile Red (NR, Chart 1b) 
was incorporated into the particles to simulate a hydrophobic active. Laser scanning confocal 
microscopy (LSCM) was used to track both fluorophores after topical application to porcine skin. 
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Porcine skin is a good substitute for human skin having epidermal thickness, lipid composition, 
permeability, transepidermal water loss and low frequency impedance values which are very 
similar.11, 12 
 
Chart 1. Chemical structures of fluorescein methacrylate (FMA) and Nile Red (NR). 
O
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(a) FMA                                     (b) NR 
 
Materials and Methods 
Tissue. Full thickness porcine skin was obtained from a local slaughterhouse. The skin was 
cleaned carefully under cold running water. The subcutaneous fat was removed with a scalpel. The 
remaining tissue was dermatomed to a thickness of ~750 µm. Finally, the dermatomed skin was 
stored frozen at -20°C for up to a maximum of one month before use. 
Chemicals. Fluorescein O-Methacrylate (97% pure), Nile Red (analytical grade) and 
polystyrene (PS, MW: 44,000) were purchased from Sigma-Aldrich (St. Louis, MO, USA).  
Styrene (99% GC), methyl methacrylate (MMA, 99% GC) and potassium persulfate (KPS) were 
purchased from Sigma-Aldrich (Gillingham, Dorset, England). Other chemicals used were 
polymethylmethacrylate (PMMA, MW = 50,000 Fluka Analytical, Steinhelm, Germany), sodium 
Page 5 of 27
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
6 
dodecylsulphate (SDS, 99+% GC, Sigma-Aldrich, Japan), ruthenium tetroxide (Taab Laboratories, 
Aldermaston, England), phosphotungstic acid (Agar Scientific Ltd., Stansted, UK), and 
chloroform-d1 (ISOTEC TM, Miamisburg, OH, USA).  
Nanoparticle (NP) Preparation. Before use, inhibitors were removed from the vinyl 
monomers by passage through an alumina column. The NP were prepared in an inert nitrogen 
atmosphere by free radical polymerization (see Scheme 1).  
 
Scheme 1. Polymerization of styrene (Reaction A) and methyl methacrylate (MMA) (Reaction B) 
with fluorescein methacrylate (FMA) using potassium persulfate (KPS) as an initiator at 75°C. 
O
O
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O
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200 cm3 distilled water was placed in a round bottom flask, with 1 g of SDS added as an 
emulsifier. The aqueous surfactant solution was deoxygenated with N2. 13 g of deoxygenated 
styrene was added into the aqueous phase. The mixture was vigorously stirred to form an emulsion 
and heated to 75°C. To start the polymerization, 0.1 g KPS dissolved in a small amount of water 
was added. The reaction was allowed to proceed under nitrogen for 3 hours. To prepare 
fluorescently labeled NP, 0.13 g of FMA and/or 0.13 g NR were mixed with the monomer before 
addition to the reaction. The same procedure was used for the preparation of PMMA NP.  
NP Characterization. The mean size and polydispersity of the NP were measured with 
dynamic light scattering (DLS BI90Plus, Brookhaven Instruments Corporation, NY, USA). The 
morphology of the nanoparticles was observed on a JEOL JEM-2000 transmission electron 
microscope (TEM) at an accelerating voltage of 120kV. Each sample was prepared by casting a 
drop of NP dispersion onto a 300-mesh copper grid covered with carbon film. TEM images of PS 
NP were obtained as positively stained preparations by placing samples in ruthenium tetroxide 
vapour for 1 hour. TEM images of PMMA NP were obtained as negatively stained preparations by 
placing samples in phosphotungstic acid for 1 hour. 1H NMR spectra were recorded in deuterated 
chloroform (CDCl3) on a Bruker Avance™ III spectrometer (Billerica, MA, USA) operating at 400 
MHz. Prior to analysis, the NP were washed with water and acetone to remove SDS and unreacted 
compounds, and freeze-dried (Heto PowerDry PL3000, Thermo Electron corporation, Waltham, 
MA, USA). 
In vitro Skin Permeation. Before the experiment, the hairs were trimmed as close as possible to 
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the skin surface. Skin permeation experiments were performed in vertical Franz diffusion cells 
thermostated at 37°C. The excised tissue was clamped between the donor and receptor compartments 
exposing a diffusion area of 3.8 cm2. The receptor compartment was filled with physiological buffer 
(pH = 7.4); the donor compartment held 1 cm3 of the NP formulation and was covered with Parafilm. 
After 6 hours of exposure, the cell was dismantled, and the skin surface was either cleaned carefully 
with physiological buffer or was simply patted dry with tissue and then immediately visualized by 
confocal microscopy.  
Laser Scanning Confocal Microscopy (LSCM). The skin was examined using a LSM 510 Invert 
Laser Scanning Microscope (Carl Zeiss, Jena, Germany). The system was equipped with an argon laser 
(excitation line at 488 nm) and a HeNe laser (excitation line at 543 nm). A Plan-Neofluar 10×/0.3 
objective, an EC Plan-Neofluar 40×/1.30 oil DIC M27 objective and a Plan-Apochromat 63×/1.40 oil 
DIC M27 objective were used. Confocal images were obtained in the plane parallel to the sample 
surface (xy-mode), or in the plane perpendicular (optical sectioning z-stack mode).  
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Results 
NP Characterization. Table 1 summarizes the properties of the NP formulations used in the in 
vitro permeation experiments.  
Table 1. Properties of the PS and PMMA nanoparticulate (NP) formulations examineda 
NP Formulation Dyes included Mean size (nm) PIb 
PS None 28.8 0.135 
PS-FMA FMA 28.0 0.141 
PS-FMA-NR FMA and NR 30.9 0.118 
PMMA None 79.0 0.171 
PMMA-FMA FMA 99.9 0.163 
PMMA-FMA-NR FMA and NR 68.5 0.133 
a PS = polystyrene; PMMA = polymethylmethacrylate; FMA = fluorescein methacrylate; NR = Nile 
Red. 
b PI: polydispersity index of the size distribution (expressed using a 0-1 scale). 
The NP were spherical and smooth as shown in Figure 1. The mean diameter of PS NP was 
less than 50 nm, while the PMMA NP were almost twice as large; these findings were confirmed by 
dynamic light scattering.  
Proton NMR spectra of polystyrene, FMA, PMMA and the two copolymers are shown in 
Figure 2. Those of the copolymers show signals from either PS or PMMA and FMA even after 
extensive dissolution/reprecipitation, indicating that FMA is covalently bound to the polymer.  
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Figure 1. Transmission electron micrograph of PS and PMMA nanoparticles stained with ruthenium 
tetroxide (a, b and c, scale bar = 50 nm) or phosphotungstic acid (d, e, and f, scale bar = 200 nm). (a) 
polystyrene NP alone, (b) polystyrene with fluorescein methacrylate (FMA) polymerized, (c) 
polystyrene with FMA polymerized and Nile Red (NR) absorbed, (d) polymethylmethacrylate (PMMA) 
NP alone, (e) PMMA with FMA polymerized, and (f) PMMA with FMA polymerized and NR absorbed. 
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Figure 2. 1H NMR spectra for (a) PS, FMA and PS-FMA copolymer, and (b) PMMA, FMA and 
PMMA-FMA copolymer, together with the structures and chemical shift assignments of (c) PS, and (d) 
PMMA. 
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LSCM Images. Nile Red is commonly used to stain intracellular lipids, because it has an 
intense and stable red fluorescent emission under the excitation of HeNe laser at 543 nm. It is also a 
useful model for a topical/transdermal active because of its high lipophilicity (log Po/w > 3)13 and 
reasonable molecular weight (318.4 g.mol-1). FMA is a fluorescent monomer containing a 
polymerizable methyl acrylate functional group which can react with styrene and MMA. Under 
excitation at 488 nm, FMA generates a bright green fluorescence, which locates the NP as the dye is 
covalently bound to polymer. The use of NR and FMA allowed the fate of the NP and of the model 
lipophilic active to be monitored independently and simultaneously in the same experiment.  
Control Experiments. For each formulation, two control experiments were performed to 
validate the methodology used. Firstly, PS and PMMA nanoparticle formulations without FMA 
were separately applied to the skin surface. Figures 3a and 3d show the resulting confocal images, 
which manifest only very weak green fluorescence that is endogenous to the SC. When the 
fluorescently-labelled NP formulations were applied to the skin, distinctly different LSCM images 
were observed when the skin was either cleaned properly, or not cleaned at all. Figures 3b and 3e 
from the latter samples show that the NP were located in the skin furrows and around the hair 
follicles. In contrast, when the skin was cleaned (Figures 3c and 3f), there was almost no residual 
fluorescence, suggesting that the NP had remained at the surface and were then easily removed by 
the simple washing procedure.  
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Figure 3. LSCM images of the skin surface following a 6-hour application of PS (panels a, b, c) or 
PMMA nanoparticles (panels d, e, f). In panels a and d, the NP were not fluorescently labelled with 
FMA and only a weak green fluorescence from the skin itself is seen. In panels b and e, the NP were 
fluorescently tagged and the skin surface was not cleaned before imaging; bright green fluorescence 
is apparent in the skin furrows and around the hair follicles. In panels c and f, the skin surface was 
cleaned before the confocal images were obtained; only the residual autofluorescence from the skin 
is observed, suggesting that the NP had been effectively removed by the cleaning procedure. 
 
LSCM Images of Skin Treated with Dual-labelled Fluorescent NP without Surface 
Cleaning. For skin samples treated with dual fluorophore-labelled NP formulations, LSCM images 
were acquired using multitracking-mode with excitation wavelengths set at 488nm and 543nm. The 
fluorescence emission from the two dyes was captured separately and overlaid. Figure 4 and Figure 
5 illustrate the disposition of the NP and of Nile Red on and within the skin, the surface of which 
was not cleaned at the end of the application period, of the polystyrene and polymethylmethacrylate 
formulations, respectively. Location of the NP is shown by green fluorescence (from FMA 
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covalently attached to the polymer), while the presence of Nile Red is highlighted in red. For the 
polystyrene formulation, NP and NR are seen on the skin surface and show clear residence in the 
skin furrows and around the follicular openings (Figures 4a and 4b). Overlay of green and red 
fluorescence in Figure 4c clearly emphasizes the co-localization of NP and active.  
 
 
Figure 4. LSCM images (×10) from skin treated with fluorescently-labelled polystyrene NP (31 nm 
diameter) containing the model active NR. Panels a and b show fluorescence emission from the skin 
surface from the NP (panel a) and NR (panel b), respectively. Panel c shows the overlay of panels a 
and b and the co-localization of NP and “active” at the skin surface. Panels d and e illustrate 
cross-sectional images, respectively highlighting fluorescence from the NP and from NR. A distinctly 
labelled, short, trimmed hair is visible. Panel f is the overlay of panels d and e and suggests some 
permeation of released NR to the deeper skin layers. 
 
To examine the fate of the formulation as a function of depth into the skin, the tissue was 
mechanically sectioned post-treatment and then examined by LSCM at a plane beyond the 
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mechanical section. The dispositions of NP and NR are shown in Figures 4d and 4e, respectively. 
Both images highlight a short, trimmed hair shaft on which NP and NR are co-localized. Again, NP 
are at the surface and NR is seen there too. However, separation of NR from the nanoparticles is 
apparent (Figure 4f, the overlay) with some permeation of the “active” to the deeper skin layers.  
 
 
Figure 5. LSCM images (×10) from skin treated with fluorescently labelled polymethylmethacrylate 
NP (69 nm diameter) containing the model active NR. Panels a and b show fluorescence emission 
from the skin surface from the NP (panel a) and NR (panel b), respectively. Panel c shows the 
overlay of panels a and b, the presence of NP in the skin furrows and the release of NR from the NP 
at the skin surface. Panels d and e illustrate cross-sectional images, respectively highlighting 
fluorescence from the NP and from NR. Another short hair stub is visibly labelled. Panel f is the 
overlay of panels d and e and again reveals some degree of separation between NP and NR.  
 
The corresponding images for the polymethylmethacrylate NP containing NR are in Figure 5. 
Co-localization of the fluorophores in skin furrows (Figures 5a and 5b) is again observed, although 
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the overlay (Figure 5c) suggests that Nile Red has already been released to some extent at the skin 
surface. The cross-sectioned images (Figures 5d, 5e and 5f) reveal similar behaviour and again 
highlight an intensely labelled hair stub.   
LSCM Images of Skin Treated with Dual-labelled Fluorescent NP after Surface Cleaning. 
When the skin surface was properly cleaned by washing with buffer at the end of the 6-hour 
experiment (as opposed to simply drying off residual solution with a paper tissue), the LSCM 
images were significantly different. Using the dual-labelled polystyrene NP, post-cleaning there was 
very little green fluorescence visible (Figure 6a) other than that probably attributable to skin 
autofluorescence. In contrast, red fluorescence from NR was clearly visible around the corneocytes, 
presumably reflecting the affinity of the lipophilic “active” for the SC intercellular lipid domains 
(Figure 6b). Self-evidently, the overlay (Figure 6c) of Figures 6a and 6b reveals only the NR 
released from the NP prior to their removal by the surface cleaning procedure.  
Further examination of the treated skin by optically sectioning the tissue in 1µm steps is shown 
in Figure 6d. The uptake of NR into the deeper SC is apparent. The appearance of green background 
autofluorescence can also be seen and demonstrates no greater intensity than that seen in control 
(untreated) samples, confirming that this signal is not due to the presence of the 
fluorescently-labelled polymer (data not shown). 
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Figure 6. LSCM images (×63) from skin treated with fluorescently-labelled polystyrene NP (31 nm 
diameter) containing the model active. At the end of a 6-hour application, the skin surface was 
cleaned thoroughly with buffer and then dried. Panel a shows an almost complete absence of 
fluorescent NP at the surface suggesting that residual formulations had been effectively removed by 
washing. In contrast, panel b shows that NR had been released from the NP and had entered the 
lipid-rich intercellular space between the corneocytes. The overlay (panel c) and the 1 µm optical 
sections down to 10 µm (panel d) confirm the uptake of “active” into the deeper SC; the weak 
autofluorescence of the skin itself becomes progressively apparent in the later sections. 
  
The results from the polymethylmethacrylate NP, when the skin surface is properly cleaned at 
the end of the application period, are similar. Figure 7a shows that no residual fluorescence from the 
NP is visible on the skin. On the other hand, NR has been released from the NP and has remained 
on/within the SC post-cleaning (Figure 7b and overlay Figure 7c). Only on hair follicles were the 
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18 
NP incompletely removed by skin washing (Figure 7d), and co-localization with the “active” was 
apparent (Figures 7e and 7f).  
 
Figure 7. LSCM images from skin treated with fluorescently-labelled polymethylmethacrylate NP (69 
nm diameter) containing NR. After a 6-hour application, the skin was thoroughly cleaned with buffer 
and dried. Panel a shows no residual presence of NP post-washing, while panel b (and overlay panel 
c) indicates that NR was released from the NP on/into the SC. Only on hair follicles were NP retained 
after cleaning (panel d) and co-localization of NR on these appendages was observed (panel e and 
overlay panel f). 
Discussion 
The confocal images presented in Figures 4 - 7 allow the following, principal conclusions to be 
drawn: (a) NP made of polystyrene or polymethylmethacrylate do not appear able to pass beyond 
the most superficial layers of the SC following a topical application lasting 6 hours; (b) the NP 
show affinity for sequestration in skin furrows and on and around follicles; thorough cleaning can 
remove the former but not necessarily the latter; (c) the associated hydrophobic active (NR) is 
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19 
released from the NP and is able to diffuse into the deeper layers of the SC, from which it is not 
removed by surface cleaning.  
The lack of penetration of NP across intact SC is perhaps not too surprising. It is difficult to 
envisage how a NP might traverse the SC transcellularly (which would involve uptake into 
corneocytes and translocalization through these cells). Equally, transport in the intercellular 
channels (100 nm width) of a ~50 nm diameter particle also seems unlikely given that the 
intercorneocyte space is filled with multiple lipid bilayers. It is also observed in our study that ~30 
nm polystyrene nanoparticles did not penetrate beyond the SC. This observation is in agreement 
with earlier report in the literature.14 The rigidity of the NP used in this study further undermines the 
possibility of their permeation across the barrier, as has been suggested in earlier work comparing 
the uptake of a lipophilic sunscreen from a nanoemulsion and from rigid NP made of cellulose 
acetate phthalate.5 Parenthetically, from a practical standpoint, the fact that NP are retarded at the 
skin surface may be a distinct advantage for a sunscreen formulation,15 especially if they are able to 
create an occlusive film as well, from which the active may be slowly released over a prolonged 
period.16  
The issue of particle rigidity has also been addressed by comparing standard lipid-based 
vesicles with specially-designed elastic species.17, 18 While the penetration of such elastic vesicles 
across the entire SC has not been equivocally demonstrated, evidence for enhanced “active” 
transport, and even for the presence of intact vesicles in deeper parts of the SC, has been reported.18  
Certainly, as has been observed here, it is clear that an “active” associated with topically 
applied NP can be released from the carrier and diffuses into the SC.4, 19, 20 As reported elsewhere,3, 6, 
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21, 22
 the delivery of the “active” will depend upon its physicochemical properties, its interaction 
with the nano-carrier, the manner of its association with the particle (surface adhesion, 
encapsulation, or a mixture of the two), as well as the dimensions and properties (hydrophobicity, 
hydrophilicity, charge, biodegradability) of the NP themselves.  
Further work may be anticipated to explore in greater depth the potential of NP formulations to 
target “actives” to the hair follicles, for example, or to create a homogeneous and substantive 
surface film from which prolonged and controlled release may be achieved. Equally, while the 
penetration of NP across intact SC seems unlikely to pose a toxicological concern, the risk 
associated with contact to a damaged or diseased skin barrier merits considerable additional 
research.  
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Glossary of Abbreviations 
 
DLS: dynamic light scattering 
FMA: fluorescein methacrylate 
KPS: potassium persulfate 
LSCM: laser scanning confocal microscope 
MMA: methyl methacrylate 
NMR: nuclear magnetic resonance 
NP: nanoparticle(s) 
NR: Nile Red 
PI: polydispersity index 
PMMA: polymethylmethacrylate 
PS: polystyrene 
SC: stratum corneum 
SDS: sodium dodecylsulphate 
TEM: transmission electron microscope 
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Legends to Table, Chart, Scheme and Figures 
 
Table 1. Properties of the PS and PMMA nanoparticulate (NP) formulations examineda 
 
Chart 1. Chemical structures of fluorescein methacrylate (FMA) and Nile Red (NR). 
 
Scheme 1. Polymerization of styrene (Reaction A) and methyl methacrylate (MMA) (Reaction B) 
with fluorescein methacrylate (FMA) using potassium persulfate (KPS) as an initiator at 75°C. 
 
Figure 1. Transmission electron micrograph of PS and PMMA nanoparticles stained with ruthenium 
tetroxide (a, b and c, scale bar = 50 nm) or phosphotungstic acid (d, e, and f, scale bar = 200 nm). (a) 
polystyrene NP alone, (b) polystyrene with fluorescein methacrylate (FMA) polymerized, (c) 
polystyrene with FMA polymerized and Nile Red (NR) absorbed, (d) polymethylmethacrylate (PMMA) 
NP alone, (e) PMMA with FMA polymerized, and (f) PMMA with FMA polymerized and NR absorbed. 
 
Figure 2. 1H NMR spectra for (a) PS, FMA and PS-FMA copolymer, and (b) PMMA, FMA and 
PMMA-FMA copolymer, together with the structures and chemical shift assignments of (c) PS, and (d) 
PMMA. 
 
Figure 3. LSCM images of the skin surface following a 6-hour application of PS (panels a, b, c) or 
PMMA nanoparticles (panels d, e, f). In panels a and d, the NP were not fluorescently labelled with 
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FMA and only a weak green fluorescence from the skin itself is seen. In panels b and e, the NP were 
fluorescently tagged and the skin surface was not cleaned before imaging; bright green fluorescence 
is apparent in the skin furrows and around the hair follicles. In panels c and f, the skin surface was 
cleaned before the confocal images were obtained; only the residual autofluorescence from the skin 
is observed, suggesting that the NP had been effectively removed by the cleaning procedure. 
 
Figure 4. LSCM images (×10) from skin treated with fluorescently-labelled polystyrene NP (31 nm 
diameter) containing the model active NR. Panels a and b show fluorescence emission from the skin 
surface from the NP (panel a) and NR (panel b), respectively. Panel c shows the overlay of panels a 
and b and the co-localization of NP and “active” at the skin surface. Panels d and e illustrate 
cross-sectional images, respectively highlighting fluorescence from the NP and from NR. A distinctly 
labelled, short, trimmed hair is visible. Panel f is the overlay of panels d and e and suggests some 
permeation of released NR to the deeper skin layers. 
 
Figure 5. LSCM images (×10) from skin treated with fluorescently labelled polymethylmethacrylate 
NP (69 nm diameter) containing the model active NR. Panels a and b show fluorescence emission 
from the skin surface from the NP (panel a) and NR (panel b), respectively. Panel c shows the 
overlay of panels a and b, the presence of NP in the skin furrows and the release of NR from the NP 
at the skin surface. Panels d and e illustrate cross-sectional images, respectively highlighting 
fluorescence from the NP and from NR. Another short hair stub is visibly labelled. Panel f is the 
overlay of panels d and e and again reveals some degree of separation between NP and NR.  
Page 26 of 27
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
27 
 
Figure 6. LSCM images (×63) from skin treated with fluorescently-labelled polystyrene NP (31 nm 
diameter) containing the model active. At the end of a 6-hour application, the skin surface was 
cleaned thoroughly with buffer and then dried. Panel a shows an almost complete absence of 
fluorescent NP at the surface suggesting that residual formulations had been effectively removed by 
washing. In contrast, panel b shows that NR had been released from the NP and had entered the 
lipid-rich intercellular space between the corneocytes. The overlay (panel c) and the 1 µm optical 
sections down to 10 µm (panel d) confirm the uptake of “active” into the deeper SC; the weak 
autofluorescence of the skin itself becomes progressively apparent in the later sections. 
 
Figure 7. LSCM images from skin treated with fluorescently-labelled polymethylmethacrylate NP (69 
nm diameter) containing NR. After a 6-hour application, the skin was thoroughly cleaned with buffer 
and dried. Panel a shows no residual presence of NP post-washing, while panel b (and overlay panel 
c) indicates that NR was released from the NP on/into the SC. Only on hair follicles were NP retained 
after cleaning (panel d) and co-localization of NR on these appendages was observed (panel e and 
overlay panel f). 
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